ADFRAR 40MG INJECTION

Adfrar 40mg Injection is a targeted anticancer medication used in the treatment of certain types of cancer. It contains trastuzumab, a monoclonal antibody designed to specifically target HER2-positive cancer cells. By attaching to HER2 receptors, it helps slow down or stop the growth and spread of cancer cells, improving treatment outcomes when administered under medical supervision.

Adfrar 40 mg Injection is commonly prescribed for HER2-positive breast cancer and gastric cancer as part of combination chemotherapy or targeted therapy regimens. Its precision-based mechanism makes it an important option in modern oncology treatment protocols. Regular monitoring and professional administration are essential to ensure safety and effectiveness.

Adfrar 40mg Injection ensures reliability, purity, and consistent therapeutic performance. It is supplied to hospitals, oncology centers, and global pharmaceutical markets for advanced cancer care.

Product Features

• Contains Trastuzumab 40mg
• Targeted therapy for HER2-positive cancers
• Monoclonal antibody formulation
• Used in combination or standalone oncology therapy
• High-quality sterile injectable preparation

How It Helps

• Targets HER2-positive cancer cells
• Slows or stops cancer cell growth
• Improves the effectiveness of chemotherapy
• Supports advanced cancer management